share_log

Goldman Sachs Maintains Neutral on LifeStance Health Gr, Raises Price Target to $9

Goldman Sachs Maintains Neutral on LifeStance Health Gr, Raises Price Target to $9

高盛对LifeStance Health Gr保持中立,将目标股价上调至9美元
Benzinga ·  03/04 09:32

Goldman Sachs analyst Jamie Perse maintains LifeStance Health Gr (NASDAQ:LFST) with a Neutral and raises the price target from $8 to $9.

高盛分析师杰米·珀斯维持LifeStance Health Gr(纳斯达克股票代码:LFST)为中性,并将目标股价从8美元上调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发